Get 250+ investors tailored to your startup

Invest in your industry and stage
Emails & contact info included
Excel and CSV export
Automatically

Trusted by 3,000+ startups

Top 50 Medical VC (Venture Capital) Funds in United Kingdom in October 2024

Last updated: Oct 2024 A list of 50 VC (Venture Capital) funds that invest in Medical startups based in United kingdom. We rank investors based on the number of investments they made in Medical companies from United kingdom. We update this investor list every month.

Top 50 Medical VC (Venture Capital) Funds in United Kingdom in October 2024

Investor	Medical United Kingdom investments
Parkwalk Advisors	25
UK Innovation & Science Seed Fund	21
Oxford Science Enterprises	19
Deepbridge Capital	19
Scottish Enterprise	19
Oxford Technology Management	16
Oxford Science Enterprises	15
SOSV	15
Archangels	14
Scottish Investment Bank	13
Mercia Fund Managers	13
Development Bank of Wales	12
GM&C Life Sciences Fund	12
AlbionVC	12
Newable Private Investing	11
Catapult Ventures	11
Oxford Capital	10
Cambridge Innovation Capital	10
M Ventures	10
Northstar Ventures	9
IP Group	9
Nesta Ventures	9
Providence Investment Company Limited	8
Praetura Ventures	8
Wellcome Trust	8
Business Growth Fund	8
Future Planet Capital	7
Foresight Group	7
SyndicateRoom	7
Epidarex Capital	6
Tern	6
Innovate UK	6
Oxford Investment Consultants LLP	6
SIS Ventures	6
Crista Galli Ventures	6
Calculus Capital	6
Nina Capital	6
Kindred Capital	5
Salica	5
Taiho Ventures	5
VentureFounders	5
Octopus Ventures	5
Hoxton Ventures	5
Angels 5K	5
Woodford Investment Management	5
QUBIS	5
Kelvin Capital	5
Co-FundNI	5
Invest Northern Ireland	5
Syncona Partners LLP	5

Find investors that fund startups like yours. Automatically.

Our algorithm will find investors that invest in your industry, stage, and geography.

Investor list

Parkwalk is a London-based fund management firm. Parkwalk invests in UK technology companies that have IP backing and freedom to operate, generally spun out of UK universities. Their funds seek to generate capital gains for their investors, enhanced by the attractive tax relief provided by EIS. Parkwalk entered this investment sector in 2009,anticipating a wave of tax-efficient incentives launched by the UK Government to stimulate innovative emerging technology companies and thereby help drive economic growth.Parkwalk utilises academic, technology transfer, venture capital and personal networks developed over many years to gain access to the highest calibre deal-flow. In 2017 Parkwalk joined forces with IP Group plc, a leading intellectual property commercialisation company that is listed on the Main Market of the London Stock Exchange under the ticker symbol IPO. As at March 2019 the combined group has net assets of £1.2bn.

Investment focus

Biotechnology, Health Care, Software
Seed, Series A, Series B
United Kingdom, United States, Philippines

Portfolio highlights

Evoralis — Utilise Our Innovative Enzymes to Efficiently Recycle Plastics Into High-Quality Raw Materials
PhoreMost — PhoreMost is a new-model drug discovery company based in Cambridge, UK: Using its core expertise to open up new ‘druggable’ target space and working with a global network of co-invested academic and industrial collaboration partners, we aim to bring a wide array of novel ‘targeted’ therapies more efficiently to market and pass these cost savingsonto patients.
OW Smell Made Digital — OW Smell Made Digital offers software and hardware solutions for controlling smell.

UKI2S, formally the Rainbow Seed Fund, is an investment fund backed by the government, providing seed funding to science & technology start-ups and SMEs

Investment focus

Biotechnology, Health Care, Medical
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

HonuWorx — HonuWorx is a technology company providing autonomous systems aimed at lowering both expenses and the environmental impact of operating robotic systems. The company's software technology is an edge-cloud architected communications and control platform that enables geographically distributed stakeholders to see data, collaborate, supervise, andcontrol robotic systems that are beyond line-of-sight.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
Wave Photonics — Wave Photonics utilizes computational techniques to accelerate integrated photonics product designs.The company is developing a platform that provides optimized designs and streamlined integration between the supply chain using a software tool for predicting the performance and variation of a component for a given fabrication process and anoptimizer to generate a foundry-specific component library.Wave Photonics is headquartered in Bristol, Bristol.

Oxford Science Enterprises is the university-partnered venture firm. We work with the University of Oxford to build companies that create fundamental technologies: science-based businesses capable of tackling the planet’s toughest problems. We invest in life science, AI and software, healthcare, and deep tech to create companies taking onchallenges like nuclear fusion, quantum computing and developing treatments and cures for infectious diseases. Founded in 2015, we’ve raised over £600M to create a world-class technology ecosystem, and combine our deep experience with a network of investors, entrepreneurs and sector-experts to find co-investment, build businesses, and hire senior management talent.

Investment focus

Health Care, Biotechnology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Finland

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Fractile — Fractile is building chips to run large language models two orders of magnitude faster. Existing hardware is good for training LLMs, but very poorly suited to subsequent inference of the trained model, which is increasingly the dominant workload. A network’s weights need to be moved onto a chip once per word generated, and this movement takes a fewhundred times longer than the subsequent computations themselves. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale.
Amber Therapeutics — Developing intelligent bioelectrical therapies that can adapt, respond and learn from each person's individual physiology

Deepbridge is a different kind of investment manager. They work closely with financial advisers and investors to design innovative products, ranging from investment in technology growth companies to asset-backed renewable energy projects. They also partner with innovative and committed management teams to help UK based companies realise theirpotential and become successful leading-edge businesses.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Australia, Singapore

Portfolio highlights

AI-Sight — AI-Sight is a startup that is developing an AI diabetic retinal screening system to deliver WHO-recommended diabetic eye screening services.
Microplate Dx — Safeguarding against the spread of antimicrobial resistance worldwide.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Scotland's business advice, support and funding agency. Explore our products and services to find the right support for your business and apply online today.

Investment focus

Biotechnology, Software, Health Care
Grant, Funding Round, Seed
United Kingdom, United States, Japan

Portfolio highlights

MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.
ILC Therapeutics — ILC Therapeutics Ltd is an early-stage biotechnology company focused on modulating the Innate Immune System through the development of novel peptide therapeutics for the treatment of Covid-19, Cancer, Atopic Dermatitis, and Psoriasis.

Oxford Technology's SEIS fund and EIS fund enable private investors to access high growth technology startup opportunities and support UK innovation. SEIS and EIS tax reliefs offer downside protection, whilst gains can be tax free.

Investment focus

Biotechnology, Health Care, Software
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

OxCan — Enabling curative cancer treatment through early detection
Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
MitoRx Therapeutics — Developing revolutionary mitochondrial-protective therapeutics which reverse mitochondrial dysfunction to arrest decline in muscular dystrophy and neurodegeneration. MitoRx Therapeutics' first-in-class first-in-target platform has potential to arrest the progression of some of the most challenging diseases.

Investment focus

Biotechnology, Health Care, Software
Series A, Seed, Series B
United Kingdom, United States, The Netherlands

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Oxford Endovascular — Oxford Endovascular are developing a novel treatment for treating brain aneurysms. The Oxford technology uses a special laser-cut metal alloy which has a shape-memory. It can be posted into a catheter during surgery, inserted into the brain and opened up into a tiny tube mesh (‘flow diverter’) that fits into the natural shape of the blood vessel.This diverts the blood away from the aneurysm, allowing it to heal.
Grey Wolf Therapeutics — By targeting the ERAP proteases in the antigen presentation pathway Grey Wolf aims to change the antigen repertoire in cancer.

SOSV is a global, deep tech venture capital firm that operates the HAX and IndieBio startup development programs focused on human and planetary health. SOSV invests $500,000 in startups at their inception as they onboard either HAX or IndieBio for a 4-6 month period designed to accelerate the raise of their next institutional round. SOSV joins thelater rounds of HAX and IndieBio graduates. HAX, based in a 35,000 sq ft facility in Newark, NJ, is equipped with machine tools, 3D printers, chemical, electrical and mechanical engineering labs, as well as on-staff engineering and design experts. SOSV's IndieBio has locations in NYC and San Francisco, both of which offer extensive services and facilities to founders including on-site BSL-2 labs, well equipped lab benches and hoods, and advanced lab equipment, such as chromatography equipment.

Investment focus

Biotechnology, Health Care, Software
Seed, Convertible Note, Pre-Seed
United States, India, United Kingdom

Portfolio highlights

MixRift — MIXRIFT - game developers specialized in Mixed Reality
unspun — From 3D scan to perfect fitting custom jeans. unspun makes each pair of jeans unique to your actual body and design. On a mission to reduce global carbon emissions by 1%. As seen in Fast Company's World Changing Ideas, Time's Best Inventions, and PopSci's Best of What's New. Welcome to the future of apparel.
Mesa Quantum — Unlock the potential of chip-scale quantum sensing for enhanced Position, Navigation, And Timing capabilities. Explore Mesa Quantum's practical solutions.

Established in 1992. Archangels is the oldest continuously operating business angel syndicate in the World. Investing in IP-rich tech & life sciences companies in Scotland, UK.

Investment focus

Software, Biotechnology, Health Care
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
1inhaler — 1inhaler operates as a developer of drug delivery device.
iGii — Integrated Graphene enable better products with a revolutionary design for manufacture process producing the world's highest quality pure 3D Graphene Foam, Gii.

Speak with our Entrepreneurship Team, who can help you find sources of finance, engage with funders and secure investment to grow your business.

Investment focus

Software, Biotechnology, Information Technology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Bio-Images Drug Delivery — BDD Pharma combine drug delivery expertise and clinical capabilities to accelerate product development pipelines, enable life cycle management and new innovative pharmaceutical products. Rapid parallel clinical testing with SWIFT significantly reduces time from product concept to clinical success.
IOTech — Discover IOTech Systems, the open edge data platform for developing, deploying, and managing Industrial Edge applications at scale. Find out more here.
Administrate — Manage 100% of enterprise training operations with configurable training management software, designed to scale with your organization.

Mercia Asset Management provides equity and debt to UK businesses with growth ambition. We are your investment partners from scale-up to exit.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States, Hungary

Portfolio highlights

Kuano — Kuano provides innovative quantum and AI solutions for drug discovery and design. It offers a discovery platform that combines target quantum mapping and AI-led chemistry to enable the faster development of better drug candidates.
MGISS — Independently advising on the smarter use of Geospatial data, technology and the digital transformation of field operations.
Workbuzz — Give your Everyday Heroes a voice with employee surveys. Our flexible and simple survey platform reaches all employees, wherever they are. Book a demo now!

Development Bank of Wales is formed in 2001 by the Welsh Assembly Government. Development Bank of Wales is an independent company, providing commercial funding to Welsh SMEs. They invests private and public funds, including EU funds.

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Debt Financing
United Kingdom, Australia, United States

Portfolio highlights

PlantSea — PlantSea manufactures and develops sustainable products using seaweed and aquaculture materials. It offers bioplastics items as biodegradable alternatives. PlantSea is based in Gaerwen, England.
Menna — Be smarter about money and grow faster with Menna. Take control of your business finances today!
Awen Oncology — Delivering first-in-class therapeutics that target novel, undrugged cancer-specific factors, offering new hope for patients around the world.

The GM&C Life Sciences Fund is a seed and early stage venture capital fund targeting life sciences businesses located in the Greater Manchester and Cheshire & Warrington region. The Fund is managed by Catapult Venture Managers ("Catapult Ventures").The Fund is based at Alderley Park, which is well recognised as a site ofnational importance, being the largest life sciences campus of its kind in the UK with more than 500,000 sq. ft. of top-end laboratory and related space and facilities. Until recently, the Park was the R&D headquarters for AstraZeneca.Since 2002, Catapult Ventures has backed a significant number of companies across a broad range of life sciences, including therapeutics (such as Abzena and Oxford BioTherapeutics), medical devices (such as Monica Healthcare and Probe Scientific), contract research organisations (such as R5 Pharmaceuticals and FDAS), diagnostics developers (such as Lumora and Biofortuna), as well as developers of technology used in healthcare applications (such as Oxford Cryosystems and Accutronics). The Fund is the result of a collaboration between Cheshire and Warrington Enterprise Partnership, Greater Manchester Combined Authority, Cheshire East Council, and Manchester Science Partnerships.

Investment focus

Health Care, Biotechnology, Medical
Seed, Funding Round, Series A
United Kingdom, Italy, Germany

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Flynotes — Flynotes is a digital software platform helping dentists deliver personalised patient care
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.

AlbionVC supports visionary founders with long-term capital and scale-up expertise. Founded in 1996, today we are partners to UK early-stage B2B software and healthcare companies. AlbionVC manages c. $1 billion of venture funds, currently invested in over 50 companies. AlbionVC is the technology investment arm of Albion Capital Group LLP, which isauthorised and regulated by the Financial Conduct Authority.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Funding Round, Seed
United Kingdom, United States, France

Portfolio highlights

tem. — In a few simple steps we can manage your renewable energy needs forever.
Treefera — Treefera is transforming the way the world approaches forest data and conservation, to create a clear future for the carbon market and the planet.
Infact Systems — Infact Systems is a company that focuses on bringing affordability and credit information into the 21st century. They facilitate the sharing of real-time, contextual data, primarily in the banking industry. Their mission is to increase responsible financial behavior by providing real-time data for modern credit. They offer integration andcustomization services for HPZone, particularly in terms of connecting with external laboratory systems. Infact Systems also provides services to help women take control of their finances.

Newable: Helping over 20,000 businesses thrive annually with tailored financial products, advice, and flexible workspace solution

Investment focus

Software, Health Care, Biotechnology
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Delta g — Delta g Limited is a quantum technology and gravity gradiometry company. A spin-out from the University of Birmingham our technology has applications in industries as varied as civil engineering, infrastructure, defence, rail, navigation and resource exploration. Experts from science, engineering an
Weldfast — Weldfast is a manufacturer and supplier of welding consumables, abrasives, chemicals, premium gas equipment, and safety products.
EarSwitch — Empowering new ways to control and connect with the world through in-ear biometric switch and sensor technology

The team behind Catapult Ventures are among the most experienced venture capital investors in the UK.Their experience spans a range of sectors from healthcare and pharmaceuticals to luxury consumer brands, manufacturing and software, as well as all stages: from start-ups and pre-revenue IP developers to company floatation and billions of poundsin revenue. Their administration team is equally experienced with each member having more than 10 years experience in a venture capital environment.

Investment focus

Health Care, Biotechnology, Medical
Funding Round, Seed, Series A
United Kingdom, United States, Israel

Portfolio highlights

CroBio — Crobio presents an environmentally sustainable solution for reducing global water consumption and preventing agricultural drought.
QV Bioelectronics — Manchester-based start-up QV Bioelectronics is developing innovative electrotherapy devices for the treatment of certain types of brain tumours.
Pencil Biosciences — Next Generation Genome Editing Tool

Helping individuals and institutions invest in Venture Capital, Infrastructure and Media companies since 1999.

Investment focus

Software, Health Care, Biotechnology
Funding Round, Seed, Series A
United Kingdom, United States, France

Portfolio highlights

Ittybit — Ittybit is a API that enables users to handle rich media in applications. It provides developers with basic techniques for uploading, storing, transforming, and extracting data from video, music, and image files.
HealthKey — HealthKey is a platform that connects employers and insurers with health providers.
Noggin HQ — The next generation of credit referencing is coming. Look busy.

Cambridge Innovation Capital backs life sciences and technology companies with an affiliation to Cambridge, Europe’s capital for innovation. As a preferred investor for the University of Cambridge, they have unparalleled access to investment opportunities in the ecosystem.Since our inception in 2013, they have raised £275 million to invest indisruptive, deep-tech businesses in sectors including, but not limited to, artificial intelligence, the internet of things, quantum technologies, autonomous systems, therapeutics, medtech/diagnostics, digital health, and genomics/proteomics.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United Kingdom, United States, Ireland

Portfolio highlights

Riverlane — Riverlane's mission is to make quantum computing useful far sooner than previously imaginable, starting an era of human progress as significant as the industrial and digital revolutions.
Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
T-Therapeutics — T-Therapeutics is a expertise in mouse genome engineering, deep expertise in biopharmaceutical drug development, single cell genomics, machine-learning and structural biology, anchored in a culture of creativity and collaboration. .

Merck Ventures is the strategic, corporate venture capital arm of Merck. Its mandate is to invest in innovative technologies and products with the potential to significantly impact Merck‘s core business areas. From its headquarters in Amsterdam and offices in the US and Israel we invest globally in transformational ideas driven by greatentrepreneurs. Merck Ventures takes an active role in its portfolio companies and teams up with entrepreneurs and co-investors to translate innovation towards commercial success. Merck Ventures has a significant focus on early-stage investing and company creation including the creation of spin-offs to leverage Merck‘s science and technology base.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Seed
United States, Switzerland, United Kingdom

Portfolio highlights

Anjuna — Anjuna confidential cloud software establishes a secure enclave that isolates and encrypts applications and data in runtime, at rest, and on the network for end-to-end data protection
Formo — We're Formo, the future of dairy. Using micro fermentation, we create animal-free cheeses that humans love.
NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.

Northstar Ventures invests venture capital in early and later stage, high growth companies tackling global challenges, focusing on climate tech and healthy ageing.

Investment focus

Software, E-Commerce, SaaS
Seed, Funding Round, Series A
United Kingdom, United States, Indonesia

Portfolio highlights

Lightox — Lightox has developed a unique range of molecular tools for use in imaging, therapeutics and assay development. These unique probes are smaller than any other commercially available fluorescent product. They offer the option of using our technologies as freely-moving probes that readily incorporate into cells or with a range of flexible linkers togive specificity to your unique applications and research needs.
DayaTani — DayaTani supplies farmers with comprehensive services to increase their productivity.
Circadacare — Circadacare helps elderly people and people with dementia live independently for longer with an integrated circadian lighting and home health monitoring system.

IP Group's core business is the creation of value for its shareholders and partners through the commercialisation of intellectual property originating from research intensive institutions. Their strength lies in managing this process from finding suitable intellectual property to commercialise to either helping develop businesses and createvalue out of them, or identifying and establishing appropriate commercial partnerships to do so. IP Group's extensive expertise in this area combined with its inside knowledge of both industry and finance have enabled the group to create a formidable track record of consistently delivering excellent results for their companies, for their partners and for their shareholders.

Investment focus

Health Care, Biotechnology, Therapeutics
Seed, Series A, Series B
United Kingdom, United States, Australia

Portfolio highlights

Microbiotica — Microbiotica is a developer of human microbiome therapeutics intended to discover and develop live bacterial therapeutics and biomarkers. The company's therapeutics identify gut bacteria linked to phenotype with unprecedented precision, enabling researchers to phenotype before testing of candidate bacteria in advanced human in vitro and invivo models.
MISSION Therapeutics — Deubiquitylating enzymes: multiple drug opportunities across therapeutic areas
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

We bring bold ideas to life to change the world for good.

Investment focus

Biotechnology, Medical Device, Medical
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Citymart — Citymart powers cities to deliver services that work. Following best practices developed with leading cities around the world, Citymart connects cities and revolutionizes the way cities frame needs, complete procurements, and improve service delivery. Over 100 cities in 35 countries have adopted Citymart tools and methods to-date.
Featurespace — Featurespace™ is the world leader in Enterprise Financial Crime prevention for fraud and Anti-Money Laundering. Featurespace invented Adaptive Behavioral Analytics and Automated Deep Behavioral Networks, both of which are available through the ARIC™ platform, a real-time machine learning software that risk scores events in more than 180 countriesto prevent fraud and financial crime.ARIC™ Risk Hub uses advanced, explainable anomaly detection to enable financial institutions to automatically identify risk, catch new fraud attacks and identify suspicious activity in real-time. More than 30 major global financial institutions are using ARIC to protect their business and their customers. Publicly announced customers include HSBC, TSYS, Worldpay, NatWest, Contis, Danske Bank, ClearBank, Akbank and Permanent TSB.
Radio Physics Solutions — Radio Physics Solutions is a security and investigation company that specializes in the fields of real-time concealed threat detection, Up to 30m Distance, autonomous, and unobtrusive. It specializes in providing early warning of threats concealed under peoples’ clothes, and so reduce the number of casualties caused by terrorists and criminalsglobally at schools, train stations, airports, government and military installations, tourist attractions and entertainment venues.Radio Physics Solutions was founded in 2009 and headquartered in Cambridgeshire, United Kingdom.

Providence Investment Company

Investment focus

Biotechnology, Biopharma, Medical
Funding Round, Series B, Seed
United Kingdom

Portfolio highlights

evonetix — Spearheading a radical new approach to gene synthesis to improve access to high-quality, gene-length DNA. Redefine possible.
DefiniGEN — Generate metabolic disease phenotypes in primary-like human cells using the best-in-class human iPSC differentiation platform. Find out more here!
CellCentric — CellCentric’s primary programme targets a deubiquitinase (DUB) enzyme which is strongly associated with prostate cancer, a leading cause of mortality among men. The target modulates the androgen receptor pathway and can potentially combat the multiple resistance mechanisms seen with recently approved prostate cancer drugs such Xtandi and Zytiga.The programme also has potential clinical utility in non-small cell lung, breast and colon cancer.

Praetura Ventures has been supporting entrepreneurs with more than money since 2011. Click to find out more about how we can help businesses and investors.

Investment focus

Software, Health Care, Information Technology
Funding Round, Seed, Series A
United Kingdom

Portfolio highlights

ScubaTx — ScubaTx is a breakthrough organ preservation device organ transplant. The ScubaTx device will leverage world-leading expertise in software design to commercialise a proven but unexploited organ preservation technique, Persufflation. ScubaTx will offer healthcare providers significant net savings, an
Cytix — Cytix is a vulnerability management software platform and cluster of dedicated pentesters to help you identify & resolve Vulnerabilities. Reach us & get a free trial of tool.
Ocula Technologies — Harness the power of advanced analytics with our sustainable growth platform enabling brands and retailers to outperform competitors.

Wellcome Trust is a medical research charity that funds research that aims to protect and improving human and animal health. It focuses on the fields of public engagement, investments, innovation, humanities, and social science. It was founded in 1936 and headquartered in London, England.

Investment focus

Biotechnology, Health Care, Pharmaceutical
Grant, Series C, Funding Round
United States, United Kingdom, Germany

Portfolio highlights

Vaxxas — Vaxxas develops and commercializes needle-free vaccine delivery system. Vaxxas was incorporated in 2011 and is based in Brisbane, Australia.
DataDotOrg — data.org brings together philanthropy, technology, academia, and social impact organizations to build the field of data science for social impact.
Feinstein Institute for Medical Research — Feinstein Institute For Medical Research is the research arm of Northwell Health, the largest health care provider and private employer in New York State. Home to 50 research labs, 3,000 clinical research studies and 5,000 researchers and staff, the Feinstein Institutes raises the standard of medical innovation through its five institutes ofbehavioral science, bioelectronic medicine, cancer, health innovations and outcomes, and molecular medicine. We make breakthroughs in genetics, oncology, brain research, mental health, autoimmunity, and are the global scientific leader in bioelectronic medicine – a new field of science that has the potential to revolutionize medicine.

BGF is the most active equity investor in the UK and Ireland, providing long-term, minority investment to growing companies.

Investment focus

Software, Information Technology, Manufacturing
Funding Round, Series A, Private Equity
United Kingdom, Ireland, United States

Portfolio highlights

FluoRok — By employing our patented technology, we can produce fluorochemicals without the production of toxic and highly dangerous hydrofluoric acid
Kubus — Trusted by government andmulti-nationals locally and abroad. Want to know more about how Kubus can help your organisation?
ER Productions — ER Productions is an innovative laser and SFX specialist providing cutting edge laser and special effects products and choreography to some of the largest shows on earth

Brilliant Ideas. Brilliant People. Brilliant Minds.

Investment focus

Biotechnology, Health Care, Software
Funding Round, Seed, Convertible Note
United Kingdom, United States, Canada

Portfolio highlights

44.01 — We offer a permanent CO2 storage solution using the natural power of mineralisation
Wittaya Aqua — A better approach to aquaculture management
Armada Technologies — Armada Technologies created the world's first Passive Air Lubrication technology. This award-winning technology operates in a passive mode and allows for discrete control of system output while completely decoupling system lubrication from ship speed. In doing so, PALS can provide appropriate boundary layer aeration under every operatingstate.

Foresight Group is a listed infrastructure and private equity investment manager which has been managing funds on behalf of institutions and retail clients for more than 35 years. Foresight has over £7.2 billion of assets under management across a number of funds on behalf of some of the world’s largest institutional investors, family offices,private and high net-worth individuals and retail investors. Foresight's investment strategies are underpinned by a strong environmental, social & governance (“ESG”) focus, which increasingly meets the demands of today’s investors and ensures we are consistently working towards creating a sustainable legacy for future generations.

Investment focus

Software, Manufacturing, Health Care
Funding Round, Private Equity, Seed
United Kingdom, United States, Jersey

Portfolio highlights

VividQ — Our holographic technology is uniquely positioned to enable truly immersive AR gaming experiences through four key features.
Hexarad — Hexarad is a radiologist-led radiology company, which combines powerful tech and expert people to provide quick, accurate diagnoses. We have developed the Hexarad Platform, a unique and all-encompassing radiology solution powered by an intelligent allocative efficiency engine.
DP Medical Systems — DP Medical Systems is a medical supplies company that offers equipment and instruments for ENT professionals.

Our EIS and SEIS funds gives investors access to some of the UK's most promising startups. The Access EIS Fund co-invests with leading angel investors to build diversified portfolios based on data, while our SEIS fund lets investors back pre-seed B2B SaaS companies selected and fostered by leading fund Founders Factory.

Investment focus

Health Care, Software, Medical
Seed, Equity Crowdfunding, Funding Round
United Kingdom, United States, India

Portfolio highlights

Heatio — Heatio provides affordable renewable energy to homeowners.
Noggin HQ — The next generation of credit referencing is coming. Look busy.
Unibloom World — Unify targets with operational projects, make scenario simulations with cost impact in real time, compare new ideas, optimise actions and turn it into actionable projects with clear financial, regulations and business impact. Release burden from Sustainability Teams!

Epidarex Capital invests in early-stage, high growth life science and health technology companies in under-ventured markets. Its international team is led by Sinclair Dunlop, Kyp Sirinakis and Liz Roper. With offices in the United States and United Kingdom Epidarex Capital’s investors represent a cross-section of leading universities, internationalcorporations, development agencies and financial institutions. Epidarex was created to meet the need for more sector-specific financial backing for young companies, including spin-outs from leading research universities.

Investment focus

Biotechnology, Therapeutics, Health Care
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Curve Therapeutics — Curve has developed an innovative screening platform that is transforming the discovery of first-in-class therapeutics. The platform allows functional screening of diverse, genetically encoded Microcycle™ libraries against a broad range of disease-associated targets that are present in their native conformation inside a mammalian cell. Curve isdeploying this platform to build a pipeline of novel cancer drugs.
Enterprise Therapeutics — Enterprise Therapeutics is a drug discovery company dedicated to the researchand development of novel therapies for the treatment of respiratory diseases.In diseases such as cystic fibrosis, asthma and COPD the lungs become congested with mucus leading to difficulty in breathing. New disease modifying therapies that target the underlyingmechanisms of mucus congestion will reduce the frequency of lung infections and improve patient quality of life.

Looking for an IoT investor for your start up or early stage company? Tern PLC is a venture capitalist working alongside ambitious entrepreneurs in the Internet of Things (IoT) space to deliver strategic IoT investment to grow your company.

Investment focus

Software, Information Technology, Artificial Intelligence
Funding Round, Seed, Series A
United Kingdom, United States

Portfolio highlights

Konektio — Optimize equipment performance and reduce downtime with AssetMinder's predictive maintenance and IoT solutions. Monitor energy usage and enhance operational efficiency seamlessly.
FundamentalVR — A strategic partner helping med-device leaders solve the Competency @ Scale Gap todrive commercial success.
Talking Medicines — Unlock the AI-Powered Conversational Data Intelligence for Healthcare Marketing Excellence Talking Medicines is transforming Healthcare Marketing by leveraging Advanced Data Science, Curated Large Language Models (LLMs), and Artificial Intelligence. Our mission is to unlock strategic intelligence within Healthcare Professional (HCPs) and Patient Conversational Data, providing actionable intelligence for Healthcare Marketing Agencies. Advanced-Data Science: Utilize cutting-edge data science techniques to analyze vast amounts of HCP and Patient Conversational Data, uncovering unseen intelligence that drive strategic decision-making. Curated Large Language Models: Implement expertly curated LLMs to accurately interpret and understand the difference in healthcare conversations for actionable Intelligence. Artificial Intelligence: Harness the power of AI to process and analyze Conversational Data, transforming raw information into strategic intelligence that enhances marketing efforts and ROI. Natural Language Interface: Delivers intelligence to customers through an intuitive natural language interface, making it easy to access and understand complex data. Just ask Drug-GPT what you want to know! At Talking Medicines, we are committed to revolutionizing Healthcare Marketing by providing our customers with the tools and intelligence they need to succeed in an increasingly complex and data-driven world.

Innovate UK is part of the UK Research and Innovation .

Investment focus

Health Care, Biotechnology, Software
Grant, Seed, Pre-Seed
United Kingdom, United States, Canada

Portfolio highlights

Awen Oncology — Delivering first-in-class therapeutics that target novel, undrugged cancer-specific factors, offering new hope for patients around the world.
Purple Transform — Purple Transform operates as an artificial intelligence company. Purple Transform improves decision accuracy with digital intelligence.
OW Smell Made Digital — OW Smell Made Digital offers software and hardware solutions for controlling smell.

xford Investment Consultants LLP ("OIC") advises Thompson Taraz, the Investment Manager of Oxford Technology and Innovations EIS Fund ("OTIF"). OIC is an Appointed Representative of Stoneware Captial LLP, which is authorized and regulated by the Financial Conduct Authority in the United Kingdom.The focus of OIC research ison University of Oxford spin out companies.Over the last fifteen years Oxford has produced a string of world-class spin-out companies. It is our belief that the next generation of world-class Oxford businesses is just waiting to be discovered.

Investment focus

Health Care, Software, Biotechnology
Series A, Seed, Funding Round
United Kingdom

Portfolio highlights

Diffblue — Diffblue Cover uses next generation autonomous AI to automate unit testing so that Java development teams can build better applications faster
Caristo Diagnostics — Our AI powered CaRi-Heart technology uncovers coronary inflammation, atherosclerosis, and plaque progression on cardiac CT. Learn more about our award-winning technology
Oxford Quantum Circuits — We deliver Enterprise ready quantum solutions that are hybrid workload ready

SIS Ventures has been created with the overall aim of supporting and growing high impact organisations through access to mission-aligned investment. SIS Ventures has a goal of becoming the go to investor and partner for social entrepreneurs. The fund will offer conventional financial returns alongside social and/or environmental returns byinvesting either equity or debt into purpose driven companies.

Investment focus

Biotechnology, Health Care, Medical
Seed, Series A, Funding Round
United Kingdom

Portfolio highlights

MiAlgae — MiAlgae is a new-age microalgal production company that aims to revolutionize the £340 billion global livestock feed industry by producing microalgal products – through the remediation of wastewater – as nutrient supplements for fishmeal in livestock feeds. Their microalgal products are high in omegas and proteins, both of which are required forthe production of many livestock feeds, especially in the aquaculture sector.Their production methodology uses circular economy to reduce the operating costs involved in the production of microalgae and as such allows them to compete with other supplements currently on the market.
Metacarpal — Metacarpal design upper-limb prosthetics without compromise. We aim to make the most robust, functional hand prosthesis that people love wearing because it works so effectively and looks so beautiful. Be proud to show your artificial side!
Solasta Bio — Solasta Bio develops environment-friendly products that meet a global need for new and effective crop protection.

Crista Galli Ventures invests in ambitious European healthtech companies at Seed and Series A. Our deep medical expertise, powerful network and agile approach enable founders to build important, world-class healthcare businesses.

Investment focus

Health Care, Wellness, Medical
Seed, Pre-Seed, Series A
United Kingdom, United States, Sweden

Portfolio highlights

Jude — Hey, we're Jude. A healthcare start-up on a mission is to bring bladder care into the mainstream.
Vitrue Health — At Vitrue Health, our mission is to reduce or eliminate the impact that musculoskeletal health issues have on over 40% of the population using cutting edge technology. We believe that the foundation of successful outcomes in musculoskeletal health, at every stage of the pathway, is accurate assessment. Whether it's a desk worker with early stages of neck pain or a patient having a total knee replacement, Vitrue's technology can help.
Collective Minds Radiology — Collective Minds® is the new radiology workspace. A cloud-based service for collaboration, consultation and access to new digital tools and expertise. We are building the largest global network of collective and artificial intelligence, with humans and machines.

At Calculus Capital they are specialists in creating and managing tax efficient private equity funds for the individual. Funds that are ideal for today's market - offering generous tax benefits, and significant growth potential within a sensible risk profile.They look to make £2-5 million investments in established companies with provenmanagement teams and a successful product or service. Their entrepreneurial flair, combined with their experience and sound commercial judgement has resulted in a diversified investment portfolio and an impressive track record. In June 2013 Calculus Capital was top ranked in the prestigious Martin Churchill Tax Efficient Review for the 6th year in a row. The Government has recently shown its support for EIS funds, by maintaining the five generous tax benefits and widening the scope of EIS investments. These changes benefit Calculus Capital's rigorous and proven strategy. As a result they are experiencing their strongest pipeline of prospective investments yet.

Investment focus

Biotechnology, Software, Health Care
Funding Round, Series A, Seed
United Kingdom, United States, Ireland

Portfolio highlights

WorkL — WorkL provides all the resources you need in one location to find employment, advance your career, connect with others, and communicate.
Tagomics — Tagomics transform disease diagnosis through comprehensive multitopic profiling.
MIP Discovery — MIP Diagnostics develop and manufacture molecularly imprinted polymers (nanoMIPs) that act as synthetic alternatives to antibodies for IVD and other industries.

We deploy early stage capital to fuel the growth of need-driven health technology companies.

Investment focus

Health Care, Artificial Intelligence, Software
Seed, Pre-Seed, Series A
United States, United Kingdom, Austria

Portfolio highlights

Noah Labs — Noah Labs is a compant that creates AI-powered software solutions for medical care and research that help diagnose, manage illnesses, and guide interventions.
Rivia — Integrated Clinical Trial Intelligence. Drive therapeutic evaluation and trial management with real-time insights.
Lillian Care — Lillian is building a nationwide network of health facilities in Germany.

A new model for Venture Capital where every founder we back becomes a co-owner of the fund

Investment focus

Software, Biotechnology, Information Technology
Seed, Series A, Series B
United Kingdom, Israel, United States

Portfolio highlights

LabGenius — Finding the next generation of drugs with machine learning, synthetic biology and laboratory automation
Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030
Fractile — Fractile is building chips to run large language models two orders of magnitude faster. Existing hardware is good for training LLMs, but very poorly suited to subsequent inference of the trained model, which is increasingly the dominant workload. A network’s weights need to be moved onto a chip once per word generated, and this movement takes a fewhundred times longer than the subsequent computations themselves. Fractile’s revolutionary approach to fusing computation with memory eliminates this bottleneck, and can scale to allow running the world’s largest models at a global scale.

Founded as an investment firm focusing on the most promising startups, we have evolved into a unique set of private market funds investing globally in equity and debt across complementary sectors and stages. We fuse traditional values with a contemporary approach and balance exacting processes with the agility to capture commercial opportunity andcompelling investment returns. Our continuous search for new opportunities has led us to create a balanced collection of complementary funds and relationships.

Investment focus

Software, Health Care, Financial Services
Seed, Secondary Market, Series A
United Kingdom, United States, Germany

Portfolio highlights

Saiz — Reduce e-commerce returns & increase website conversions with the most accurate size advisor. The Online Shopping revolution: SAIZ.
FullCircl — FullCircl is a Customer Lifecycle Intelligence (CLI) platform for customer-facing channels in B2B financial services. Better business, faster.
RevvedUp.ai — Effortlessly build engaging sales rooms that increase pipeline, accelerate deals and create a delightful buyer experience with our AI Sales Engine.

Taiho Ventures is a company that specializes in the research and development of pharmaceuticals.

Investment focus

Biotechnology, Health Care, Therapeutics
Series A, Series B, Series C
United States, United Kingdom, China

Portfolio highlights

Theolytics — Theolytics is a biotechnology company harnessing viruses to combat cancer. A step-change in the oncolytic viral therapy field, our phenotypic screening Platform enables the discovery and development of efficacious, targeted candidates suitable for intravenous delivery and optimised for a chosen patient population. In addition to advancing aninternal Pipeline of programs spanning both solid and liquid tumours, we are establishing select strategic partnerships to expand and accelerate pipeline development.
Libero Thera — LiberoThera provides drug discovery research and development services. It focuses on making drugs with GPCRs for membrane proteins. LiberoThera was founded in 2018 and is located in Tokyo.
Storm Therapeutics — Targeting pathways that modify RNA to deliver novel cancer therapeutics.

Volution is a UK based Venture Capital firm. We back ambitious Fintech and SaaS businesses, ready to accelerate their growth to Series B and beyond.

Investment focus

Health Care, Software, Medical
Series A, Funding Round, Seed
United Kingdom, United States

Portfolio highlights

Zopa — Zopa is a P2P money lending service that allows lenders and borrowers to deal directly with one another, cutting out the banks who act as middlemen. It works in the following way: the company first categorizes borrower credit grades with an A*, A, B, C, or Y rating; then lenders make offers that vary by money amount and time period for persons witha certain credit grade, and borrowers can then agree the aggregate offered rate.Zopa takes on such responsibilities as distributing money between parties, completing the legal paperwork, performing borrower identity/credit checks, and employing a collections agency that chases missed payments for the lender.Zopa also mitigates risk for lenders by enforcing monthly direct debit repayment, making borrowers sign a legal contract, and allowing lenders to lend small chunks of money to individual borrowers (i.e. someone lending Â£1000 would have their money spread across say, 100 borrowers).The company itself makes money by charging a fixed fee for borrowers and a 1% annual fee for lenders.Zopa has received public acclaim as well, having been awarded CNET Technology Awards' 2006 Internet Innovation of the Year, the 2007 Webby Award for Best Banking/Bill-Paying Website, the 2008 Webby Award for Financial Services, the Banker 2007 Award for Best Internet Project, and Moneywise 2009 Awards for Best Customer Service and Best Personal Loan.One of the three initial members of the UK's Peer-to-Peer Finance Association, together with FundingCircle and RateSetter. Other P2P lending services include
DeadHappy — DeadHappy is an insurtech company that provides digital pay-as-you-go life insurance services. It specializes in offering flexible life insurance policies that are designed to be cheaper, easier, and better than existing traditional providers. Its offerings include pricing insurance based on current circumstances and the option to add furthercoverage on a rolling basis.The company was founded in 2013 and is headquartered in Leicester, England.
Lightpoint Medical — Lightpoint is developing miniaturized imaging and sensing tools for advanced robot-assisted cancer surgery.

We provide venture capital investment for the people, ideas and industries that will change the world. Learn about what we do and the kind of founders we back.

Investment focus

Software, Health Care, Artificial Intelligence
Series A, Seed, Series B
United Kingdom, United States, Germany

Portfolio highlights

Desia — Desia provides advanced AI applications for productivity, automation, and analytics for financial services.
NanoSyrinx — NanoSyrinx is an award-winning, discovery stage biotechnology company based in the UK. We are using synthetic biology approaches to develop protein nanosyringes as a completely novel modality for intracellular delivery of protein and peptide biologic drugs.
Puraffinity — Puraffinity develops targeted materials for water treatment, focused on forever chemicals called PFAS. Our strategic intent is to provide 1 billion people with PFAS safe water by 2030

Hoxton Ventures focuses on startups that either disrupt existing industries or invent entirely new market categories. Hoxton typically invests between $500,000 and $5 million into pre-seed, seed, and Series A stage companies, and follows its capital through the life of the company. The firm is based in London and invests all across Europe.

Investment focus

Artificial Intelligence, Information Technology, Software
Seed, Series A, Funding Round
United Kingdom, United States, Canada

Portfolio highlights

CuspAI — CuspAI is a revolutionary AI startup that is developing a platform for next-generation materials to address global sustainability and renewable energy concerns. CuspAI uses cutting-edge generative AI, deep learning, and molecular simulation to accelerate the material design process. Their platform works similarly to a search engine for materials,allowing users to request certain properties for new materials on demand.
Malted AI — Malted AI is a developer of a low-code platform enables enterprises to build and deploy large language models-enabled applications at scale, using distillation to inject domain-specific knowledge into smaller, focused models, trained on proprietary data in a secure environment.
PACT — PACT designs Elegant materials produced in tune with the planet earth. It create revolutionary, sustainable biomaterials using the earth's resources, including collagen, herbal extracts, oils, and minerals.

Southern Angel Investors Club, combining Surrey investors Club & Angels 5K, are entrepreneurs who understand what new businesses need.

Investment focus

Biotechnology, Software, Medical
Seed, Funding Round, Angel
United Kingdom

Portfolio highlights

Celixir — Celixir is a developer of regenerative medicines created to change the lives of patients in need. The company's medicines consists of iMP cells, platelet lysate and PML cells to treat patients with ischaemic heart disease, injured tendons near the surface of the skin and mild to moderate heart failure respectively, enabling medical researchersto discover breakthrough medicines that aim to change the standard of medical care for patients.
Novastone Media — With its unique asymmetric technology, novastone puts you directly where your clients want to talk to you.
Geektastic — Geektastic guarantees hiring teams only meet high calibre candidates. Our technical code challenges quickly identify the most talented software engineers.

Woodford Investment Management is a privately owned investment firm manages equity mutual funds. At Woodford, they don’t want to be just another fund management company. They want to create something different and better for their investors and they feel strongly that existing and potential clients are entitled to understand what they are doingwith their money.As investors, they are active, engaged, long-term, disciplined, diligent and focused. That’s a lot of things to say about their selves but each word is important in helping you to understand how they manage money – they will explain in more detail as they move along.Their investment approach and process are focused on value discovery, not price discovery. They believe that financial markets are inherently inefficient and that, through disciplined and diligent analysis, they can identify investment opportunities where market prices do not reflect long-term fundamental value. By exploiting this pervasive market characteristic, they believe they can create real long-term value for their investors.

Investment focus

Biotechnology, Health Care, Medical
Series B, Series A, Funding Round
United Kingdom, United States, Ireland

Portfolio highlights

Inivata — Inivata is a clinical cancer genomics company harnessing the emerging potential of circulating DNA analysis to improve testing and treatment for oncologists and their patients.Unlike conventional invasive biopsies, Inivata detects and analyses genomic material from a cancer patient’s cell-free, circulating tumor DNA (ctDNA) which can be collectedthrough a simple blood sample. This non-invasive approach – a liquid biopsy – offers a revolution in how cancer is detected, monitored, and treated.
Revolut — Join 40+ million customers globally using Revolut to send money to 160+ countries, hold up-to 36 currencies in app, spend in 150+ currencies, and manage their money.
Atom Bank — Savings accounts, a range of mortgages & business loans, you'll find it all with Atom bank. App-based and designed to be hassle-free. Download the app today.

QUBIS Ltd was established in 1984 by The Queen's University of Belfast to commercialise the University's research and development activities through the formation of 'spin-out' businesses. Qubis Ltd is an investment vehicle, holding company which takes an equity holding in a new spin-out venture in return for an investment ofcash and/or Intellectual Property. Qubis Ltd 'pulls through' appropriate R & D from the laboratory into the commercial market place.

Investment focus

Health Care, Medical, Biotechnology
Seed, Funding Round, Pre-Seed
United Kingdom, United States

Portfolio highlights

GoPlugable — GoPlugable's innovative approach to EV charger sharing makes it easier for businesses & individuals to access and share charging infrastructure.
CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

We invest venture capital in to globally ambitious companies which have the potential to deliver a significant return to our investors

Investment focus

Health Care, Biotechnology, Manufacturing
Seed, Funding Round, Series A
United Kingdom, United States

Portfolio highlights

Chromacity — Chromacity manufacture the next generation of ultrafast lasers. Discover our fixed wavelength femtosecond lasers and picosecond OPOs.
Ingenious Audio — Ingenious Audio is a Scottish start up designing and manufacturing audio electronics."invisible guitar cable" is a compact plug in device which turns an analogue audio product, such as an electric guitar or amplifier into a wi-fi device.This system allows wireless connection of any existing guitar and amplifier; and for the firsttime will allow the use of wireless effect pedals.As the product outputs, wi-fi users can connect seamlessly to any wi-fi enabled pc, replacing the need for expensive recording and audio effects devices and crucially allows sharing of audio across the web.
Sofant Technologies — Sofant is developing a low cost RF MEMS technology that solves power consumption and heat problems in high frequency phased array antenna systems.

Through Co-Fund NI £12.5million will be made available to invest alongside business angels and business angel syndicates (hereafter referred to as "private investors" or "syndicates") into eligible SME's based in Northern Ireland. When matched 45% public with 55% private investors on a deal-by-deal basis this will give anoverall "fund" size of £28m.This initiative is provided by Invest Northern Ireland and part-financed by the European Regional Development Fund under the Invest for Growth and Jobs Programme 2014-2020.

Investment focus

Software, Health Care, Information Technology
Seed, Funding Round, Pre-Seed
United Kingdom, Ireland

Portfolio highlights

Kinsetsu — Kinsetsu provides intelligent tracking solutions to help organisations automate and optimise tasks and services.
CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.
GenoMe Diagnostics — GenoME Diagnostics - We are developing a blood test for an earlier and more accurate diagnosis of ovarian cancer.GenoME Diagnostics .

Invest Northern Ireland is Northern Ireland's economic development agency. Their overall goal is to help create wealth for the benefit of the whole community by strengthening the economy and helping it grow.

Investment focus

Health Care, Biotechnology, Medical
Funding Round, Grant, Seed
United Kingdom, United States, Ireland

Portfolio highlights

TruCorp — TruCorp: Your source for lifelike Medical Training Equipment. Explore our intubation manikins & airway trainers. Request a free demo today!
GoPlugable — GoPlugable's innovative approach to EV charger sharing makes it easier for businesses & individuals to access and share charging infrastructure.
CV6 Therapeutics — CV6 Therapeutics is a drug development company focused on the discovery, development and commercialization of novel therapies for the treatment of human diseases.

Syncona is a FTSE250 company focused on founding, building and funding healthcare companies to deliver transformational treatments to patients in areas of high unmet need.

Investment focus

Biotechnology, Therapeutics, Medical
Series A, Series B, Seed
United Kingdom, United States, Switzerland

Portfolio highlights

Spur Therapeutics — Spur Therapeutics is a clinical-stage biotechnology business dedicated to creating life-changing medicines for crippling chronic illnesses.
SwanBio Therapeutics — SwanBio Therapeutics is a gene therapy company that aims to bring life-changing treatments to people with devastating, genetically defined neurological conditions.
Yellowstone Biosciences — Yellowstone seeks to identify a novel class of frequently expressed antigens that can be therapeutically targeted, With the potential to dramatically improve patient outcomes.

Investors by industry

Artificial intelligence